Clinical trials: Prostate Cancer With Intermediate Risk
Prostate Carcinoma
An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer
The purpose of this study is to evaluate the induction of immune responses against CV9104 administered by conventional intradermal injection or with a needle-free intradermal injection device and to assess the safety and…
- Trial name
- NCT02140138
- Testing
- CV9104, needle free injection device (Tropis®)
- Where
- 3 sites in Germany
- Volunteers
- 35 people
- Sponsor
- CureVac
Prostate Cancer
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
This study evaluates the safety, anti-tumor effect, and immunogenicity of Enoblituzumab given before radical prostatectomy. All patients will receive Enoblituzumab for 6 weekly doses beginning 50 days prior to radical…
- Trial name
- NCT02923180
- Testing
- Enoblituzumab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Safety and Efficacy of Two-step Radical Prostatectomy
The goal of this observational study is to learn about the safety and efficacy of two-step radical prostatectomy in the treatment of low- to intermediate-risk prostate cancer patient with enlarged prostate and severe benign…
- Trial name
- NCT05722392
- Testing
- Two-step Radical Prostatectomy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer
This phase II trial studies how well focal radiation therapy with stereotactic body radiation therapy (SBRT) or high-dose rate (HDR) brachytherapy works in treating patients with low or intermediate-risk prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8
- Trial name
- NCT04399824
- Testing
- High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
MRI Assisted Focal Boost With HDR Monotherapy for Prostate Cancer Patients
Radiation therapy plays an important role in the management of prostate cancer. In recent years it has become evident that higher doses of radiation are required to optimize disease control.
- Trial name
- MARS (NCT02623933)
- Testing
- MRI assisted focal boost with HDR monotherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
Internal Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. PURPOSE: This clinical trial is studying the side effects and how well internal radiation therapy works in…
- Trial name
- NCT00573833
- Testing
- questionnaire administration, quality-of-life assessment, brachytherapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostatic Neoplasms
Dose Escalation For INtraprostatic LEsions
External beam radiotherapy combined with androgen deprivation therapy is a standard treatment option for localized prostate cancer.
- Trial name
- DEFINE (NCT05851547)
- Testing
- Prostate SBRT with Focal Boost, Triptorelin Injection
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- Ottawa Hospital Research Institute
Prostate Cancer, Prostate Adenoma
Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7%
The goal of this clinical trial is to evaluate efficacy and safety of radical prostatectomy (RP) with or without salvage radiotherapy versus RP with extended pelvic lymph node dissection (ePLND) in males who have localized…
- Trial name
- PRESEL (NCT07115992)
- Testing
- RARP±SRT, RARP+ePLND
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Ruijin Hospital
Prostate Cancer
Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer
To Evaluate Safety, Tolerability and Potential Efficacy of PRX302 effect on clinically significant localised low to intermediate prostate cancer.
- Trial name
- NCT02499848
- Testing
- PRX302
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Sophiris Bio Corp
Prostate Cancer
High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic Nodule
This study will investigate the feasibility of using technology of ultrasound guided HDR brachytherapy to focally increase dose to regions within the prostate that are heavily infiltrated with cancer.
- Trial name
- Dosepainting (NCT01605097)
- Testing
- HDR interstitial brachytherapy
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00026377
- Testing
- bicalutamide, flutamide, goserelin acetate
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Prostate Cancer
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for…
- Trial name
- NCT00833248
- Testing
- Degarelix, Goserelin, Bicalutamide
- Where
- 66 sites in United States, France and 5 more
- Volunteers
- 246 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform
In this non-interventional study, men being seen by urologists in the course of their normal practice that present with clinical suspicion of prostate cancer (based on DRE, elevated Prostate Specific Antigen (PSA), and/or family…
- Trial name
- NCT04100811
- Where
- 3 sites in United States
- Volunteers
- 2,019 people
- Sponsor
- miR Scientific LLC
Prostate Cancer
Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy
The purpose of this trial is to compare two similar treatments for patients diagnosed with prostate cancer. The two treatment arms being compared are: (Standard Arm) hormone therapy, which will prevent the production of the male…
- Trial name
- NCT00175396
- Testing
- Androgen suppression, radiotherapy, Androgen suppression, radiotherapy, iodine 125 brachytherapy
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- University of British Columbia
Prostate Cancer
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients…
- Trial name
- NCT04264208
- Testing
- 68-Ga RM2., 68-Ga PSMA11, PET/MRI
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Andrei Iagaru
Prostate Cancer
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT01368588
- Testing
- three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy
- Where
- 478 sites in United States, Canada and 4 more
- Volunteers
- 2,590 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Dose Escalation to Dominant Intraprostatic Lesions (DIL) With MRI-TRUS Fusion High Dose Rate (HDR) Prostate Brachytherapy
The Magnetic Resonance (MR) provides high resolution of soft tissue images allowing an appropriate assessment of the local extent of the disease.
- Trial name
- BRAPROST (NCT01909388)
- Testing
- MRI-TRUS fusion guided real time HDR
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Alfonso Gomez-Iturriaga
Prostate Cancer
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.
- Trial name
- PSMA SBRT-SIB (NCT04402151)
- Testing
- PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer
The aim of the focal treatment HIFU is to destroy the cancer without causing side effects in contrast to radical treatments. Radical treatments (surgery or radiation therapy) are the standard therapies for patient with…
- Trial name
- FOCALE (NCT03568188)
- Testing
- treatment with focal HIFU, PSA dosage, MRI
- Where
- 14 sites in France
- Volunteers
- 174 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer
The purpose of this study is to determine whether stereotactic body radiation therapy (SBRT) with simultaneous boost (higher radiation dose) to areas within the prostate with more prominent cancerous growth (intraprostatic…
- Trial name
- Prostate SBRT (NCT01409473)
- Testing
- Prostate SBRT with concurrent boost to intraprostatic lesion(s)
- Where
- 2 sites in United States
- Sponsor
- Rocky Mountain Cancer Centers